gip and glp 1 drugs GLP-1/GIP Receptor Agonists Diabetic Retinopathy: What ODs Should Know The dual agonist action of
Description
It is important to note that, in the other large type 2 diabetes cardiovascular outcome trials, there were no statistically significant associations with the use of GLP-1/GIP agonists and negative eye outcomes
doi: 10.1016/j.cmet.2012.06.015 31 AlhadeffALBairdJ-PSwickJCHayesMRGrillHJ
Published in 2016, the study showed that liraglutide reduced the risk of cardiovascular disease which is one of the most common causes of death in patients with type 2 diabetes
cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina) occurred in 109 participants
